Literature DB >> 8539405

Arterial thrombosis below the inguinal ligament: percutaneous treatment with a thrombosuction catheter.

J A Reekers1, J G Kromhout, H G Spithoven, M J Jacobs, W M Mali, L J Schultz-Kool.   

Abstract

PURPOSE: To assess the safety and clinical efficacy of using a thrombosuction catheter for treatment of arterial thrombosis below the inguinal ligament.
MATERIALS AND METHODS: The catheter was used in a consecutive group of 28 patients (10 women, 18 men; age range, 38-87 years; mean age, 66.7 years; with 11 native vessels and 17 grafts) with acute infrainguinal thrombosis. Initial local success, clinical success, and 30-day outcome were studied.
RESULTS: The initial local success rate was 82%. The clinical success rate was 73% for native vessels and 53% for grafts. The 30-day success rate was 73% for native vessels and 35% for grafts. Displacement of thrombotic material during the procedure resulted in a clinical complication in one patient. There were no bleeding complications. In 58% of all patients (n = 26), no lytic drug was used.
CONCLUSION: The thrombosuction catheter seems to be a safe, fast-acting alternative or supplement to local lysis therapy for infrainguinal arterial thrombosis.

Entities:  

Mesh:

Year:  1996        PMID: 8539405     DOI: 10.1148/radiology.198.1.8539405

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Comparison of AngioJet rheolytic pharmacomechanical thrombectomy versus AngioJet rheolytic thrombectomy in a porcine peripheral arterial model.

Authors:  Peter H Lin; Firas F Mussa; Nasim Hedayati; Joseph J Naoum; Wei Zhou; Qizhi Yao; Panagiotis Kougias; Hosam F El Sayed; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 2.  Iatrogenic percutaneous vascular injuries: clinical presentation, imaging, and management.

Authors:  Benjamin H Ge; Alexander Copelan; Dominic Scola; Micah M Watts
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.